trending Market Intelligence /marketintelligence/en/news-insights/trending/nercxxjx7lasjtsc6tezxq2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Vistin Pharma to raise 300M kroner in private placement

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

Vistin Pharma to raise 300M kroner in private placement

Vistin Pharma ASA plans a private placement for gross proceeds of up to about 300 million Norwegian kroner.

The producer of diabetes treatment metformin expects to issue up to 26,785,715 new shares directed toward Norwegian and international investors for a subscription price of 11.20 kroner per share.

Vistin Pharma's largest shareholder, Øystein Spetalen, has indicated plans to subscribe for his pro rata share of the private placement.

The application period for the placement will start March 22 and close March 23.

Oslo-based Vistin expects to use the net proceeds from the placement to fund the establishment of its energy trading business and trading activities within this area.

The company has retained DNB Markets to advise on and implement the private placement.

In case the private placement is successfully completed, the company's board will not propose a dividend to be paid as announced in a Feb. 27 release.

As of March 22, US$1 was equivalent to 7.73 Norwegian kronor.